Skip to content
My WebMD Sign In, Sign Up

Lung Cancer Health Center

Font Size

Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IIIA NSCLC Treatment

Patients with stage IIIA NSCLC are a heterogenous group. Patients may have metastases to ipsilateral mediastinal nodes, potentially resectable T3 tumors invading chest wall, or mediastinal involvement with metastases to peribronchial or hilar lymph nodes (N1). Presentations of disease range from resectable tumors with microscopic metastases to lymph nodes to unresectable, bulky disease involving multiple nodal stations.

Prognosis:

Recommended Related to Lung Cancer

Non-Small Cell Lung Cancer: Advances in Chemotherapy

Chemotherapy is being used in new ways to treat non-small cell lung cancer (NCSLC). Until a few years ago, only patients with late-stage lung cancer received chemotherapy to help prolong life. Now, chemotherapy is given at earlier stages, in addition to other treatments, to slow the progression of cancer and to help cure the disease. “Chemotherapy has dramatically improved in the last decade,” says George R. Simon, MD, FACP, FCCP, director of thoracic oncology Fox Chase Cancer Center in Philadelphia...

Read the Non-Small Cell Lung Cancer: Advances in Chemotherapy article > >

Patients with clinical stage IIIA-N2 disease have a 5-year overall survival rate of 10% to 15%; however, patients with bulky mediastinal involvement (i.e., visible on chest radiography) have a 5-year survival rate of 2% to 5%. Depending on clinical circumstances, the principal forms of treatment that are considered for patients with stage IIIA NSCLC are radiation therapy, chemotherapy, surgery, and combinations of these modalities.

Treatment options vary according to the location of the tumor and whether it is resectable.

Standard Treatment Options for Resected/Resectable Stage IIIA N2 NSCLC

Despite careful preoperative staging, some patients will be found to have metastases to mediastinal N2 lymph nodes at thoracotomy.

Standard treatment options for resected/resectable disease include the following:

  1. Surgery.
  2. Neoadjuvant therapy.
    • Neoadjuvant chemotherapy.
  3. Adjuvant therapy.
    • Adjuvant chemotherapy.
    • Adjuvant chemoradiation therapy.
    • Adjuvant radiation therapy.

The preponderance of evidence indicates that postoperative cisplatin combination chemotherapy provides a significant survival advantage to patients with resected NSCLC with occult N2 disease discovered at surgery. The optimal sequence of surgery and chemotherapy and the benefits and risks of postoperative radiation therapy in patients with resectable NSCLC are yet to be determined.

Surgery

If complete resection of tumor and lymph nodes is possible, such patients may benefit from surgery followed by postoperative chemotherapy. Current evidence suggests that lung cancer resection combined with complete ipsilateral mediastinal lymph node dissection (CMLND) is associated with a small-to-modest improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal nodes in patients with stage I, II, or IIIA NSCLC.[1][Level of evidence: 1iiA]

Evidence (surgery):

  1. The Cochrane Collaboration group reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[1] A pooled analysis of three trials reported the following:
    • Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and CMLND, compared with those who underwent resection and lymph node sampling; the hazard ratio (HR) was estimated to be 0.78 (95% confidence interval [CI], 0.65–0.93; P = .005).[1][Level of evidence: 1iiA]
  2. CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030). Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[2]

Limitations of evidence (surgery):

Conclusions about the efficacy of surgery for patients with local and locoregional NSCLC are limited by the small number of participants studied to date and by the potential methodological weaknesses of the trials.

1|2|3|4|5|6|7|8

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

lung cancer overview slideshow
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
Using GPS to Detect Lung Cancer
VIDEO
mans hand putting out cigarette
Article
 
15 Cancer Symptoms Men Ignore
FEATURE
Lung Cancer Risks Myths and Facts
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
Improving Lung Cancer Survival Targeted Therapy
VIDEO
 
Lung Cancer Surprising Differences Between Sexes
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Lung Cancer Surgery Options
VIDEO
 

WebMD Special Sections